Atsekardol tab n / an kish.rastv. 50mg 30 pc

$0.50

Atsekardol tab n / an kish.rastv. 50mg 30 pc

Quantity:

SKU: 01444061250 Categories: , , Tags: ,

Description

Composition
Active substance:
1 tablet contains: Acetylsalicylic acid – 50 mg or 100 mg or 300 mg.
Excipients:
Lactose monohydrate (milk sugar), corn starch pregelatinized, stearic acid.
shell composition: tsellatsefat (acetylphthalyl), titanium dioxide, castor oil.
Product form:
Enteric tablets, film-coated 50 mg, 100 mg, 300 mg
10 tablets in blisters. 1, 2, 3 or 5 the contour of cellular packaging together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to ASA, erosive and ulcerative lesions GIT (exacerbation), gastro-intestinal bleeding, hemorrhagic diathesis, bronchial asthma induced by intake of salicylates, full or partial combination of asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to ASA expressed kidney failure (creatinine clearance (CC) of less than 30 ml / min) expressed hepatic failure (class B and C Child-Pugh), chronic heart failure (III-IV functional class stem ssifikatsii NYHA), concomitant use of methotrexate at a dose of 15 mg / week or more, pregnancy (I and III trimester), lactation, children up to 18 years, lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
If you have one of these diseases, before taking this medication, you should consult with your doctor.
Dosage
50 mg
Indications
Prevention of acute myocardial infarction in the presence of risk factors (e.g., diabetes, hyperlipidemia, hypertension, obesity, smoking, old age), and recurrent myocardial infarction;
Unstable angina;
Prevention of ischemic stroke (including patients with transient ischemic attack);
Prevention of thromboembolism following surgery and invasive interventions on vessels (e.g., coronary artery bypass grafting, carotid endarterectomy, arteriovenous bypass grafting, angioplasty and stenting of the coronary arteries, carotid angioplasty);
Prevention of deep vein thrombosis and pulmonary embolism and its branches (including in long-term immobilization due to extensive surgery).
pharmachologic effect
Pharmacological properties:
The basis antiplatelet action mechanism of acetylsalicylic acid (ASA) is irreversible inhibition of cyclooxygenase (COX-1), resulting in blocked synthesis of thromboxane A2 and platelet aggregation is suppressed. Antiplatelet effect develops even after the application of low doses of drug and continued for seven days after a single dose. It is believed that ASA has other mechanisms of platelet aggregation suppression.
At high doses of ASA (over 300 mg / day) also has anti-inflammatory, antipyretic and analgesic action.
Pharmacokinetics:
After oral administration ASA is rapidly and completely absorbed from the gastrointestinal tract (GIT). ASA is partially metabolized in the absorption time. During and after absorption ASA converted to the major metabolite – salicylic acid, which is metabolized primarily in the liver by the enzymes to form metabolites such as phenyl salicylate, salicylic acid glucuronide and salitsilurovaya acid, found in many tissues and urine. In women, the process of metabolism is slower (lower activity in serum enzymes).
The maximum concentration of ASA in the blood plasma achieved 10-20 minutes after ingestion, salicylic acid – after 0.3-2 hours.
Because acid-coated tablet shell ASA is released not in the stomach (sheath effectively blocks the dissolution of the drug in the stomach) and in an alkaline environment of the duodenum. Thus, the absorption of ASA in the form of tablets, enteric-coated, delayed for 3-6 hours as compared with conventional (without a shell) tablets.
Salicylic acid ASA and bind to plasma proteins (from 66% to 98% depending on the dose) and rapidly distributed in the organism. Salicylic acid penetrates through the placenta and into breast milk.
Excretion of salicylic acid is dose-dependent, since its metabolism may limit enzyme system. half-life is 2-3 hours when applied at low doses of ASA and 15 hours when using the drug in high dose (usual dose of acetylsalicylic acid as an analgesic). Unlike other salicylates, when multiple dose preparation negidrolizirovannaya ACK does not accumulate in the serum. Salicylic acid and its metabolites are excreted by the kidneys. In patients with normal renal function 80-100% of a single dose of the drug is excreted by the kidneys within 24-72 hours.
Pregnancy and breast-feeding
The use of high doses of salicylates in the first 3 months of pregnancy is associated with an increased rate of fetal defects (cleft palate, heart defects). Appointment of salicylates in the I trimester of pregnancy is contraindicated. During II trimester salicylates can only be assigned with the rigorous assessment of risk to the fetus and the mother for use, preferably in doses not exceeding 150 mg / day, and short-lived.
In the last trimester of pregnancy salicylates in high doses (more than 300 mg / day) caused a weakening of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and the fetus, and the appointment just before birth may cause intracranial hemorrhage, especially in preterm infants. Appointment of salicylates in the last trimester of pregnancy is contraindicated.
Salicylates and their metabolites in small amounts into breast milk, so the lactation should be discontinued breastfeeding.
Conditions of supply of pharmacies
Without recipe.
Storage conditions
At a temperature not exceeding 25 C. Keep out of reach of children.
Dosing and Administration
Atsekardol® drug should be taken before eating, drinking plenty of fluids, 1 time per day. Atsekardol for prolonged use. The duration of therapy is determined by the doctor.
Prophylaxis with suspected acute myocardial infarction: 100 mg per day or 300 mg every other day (first pill must be chewed for faster absorption).
Prevention of new-onset acute myocardial infarction in the presence of risk factors: 100 mg per day or 300 mg every other day.
Prophylaxis of recurrent myocardial infarction and unstable angina: 100 – 300 mg per day.
Preventing ischemic stroke and transient ischemic attack: 100 – 300 mg per day.
Prevention of thromboembolism following surgery and interventional vascular procedures: 100 – 300 mg per day.
Prevention of deep vein thrombosis and pulmonary artery and its branches 100 mg per day or 300 mg every other day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SYNTHESIS

There are no reviews yet.

Add your review